Coronavirus Disease (COVID-19) Clinical Trial
Official title:
A Phase 1/Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety, Tolerability and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Younger and Older Participants
The primary objective of this early Phase 1/2 study is to identify the V591 dose that achieves the target immune response in humans based on preclinical or early clinical data.
This study was terminated and modifications to the dosing regimens and clinical/laboratory procedures were implemented for trial discontinuation according to Protocol Amendment 04. Per protocol, certain panels were never enrolled and/or the second dose of study intervention was not administered. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04583982 -
ImmuneSense™ COVID-19 Study
|
||
| Completed |
NCT04609774 -
Aerosol Transmission of Severe Acute Respiratory Syndrome Coronavirus of Coronavirus Disease 2019
|
||
| Terminated |
NCT04569786 -
Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)
|
Phase 1 | |
| Terminated |
NCT04575584 -
Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)
|
Phase 2/Phase 3 | |
| Completed |
NCT04575597 -
Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04572360 -
Cardiorespiratory Exercise & Chinese Medicine for Rehabilitation of Discharged Coronavirus Disease (COVID-19) Patients
|
N/A | |
| Recruiting |
NCT04885361 -
To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults
|
Phase 1 | |
| Not yet recruiting |
NCT04360122 -
Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19
|
Phase 3 | |
| Completed |
NCT05119855 -
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
|
Phase 3 | |
| Completed |
NCT04558307 -
Feasibility of Rapid COVID-19 Testing in Disadvantaged Populations
|
||
| Recruiting |
NCT04584606 -
Ain Shams University Experience: Clinical Determinants of Hospitalized COVID-19 Patients
|
||
| Completed |
NCT04677660 -
A Study of TAK-919 in Healthy Japanese Adults (COVID-19)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04280588 -
Fingolimod in COVID-19
|
Phase 2 | |
| Completed |
NCT04941144 -
Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination
|
||
| Completed |
NCT04939428 -
Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
|
Phase 3 | |
| Withdrawn |
NCT04892888 -
Survey of the Moderna COVID-19 Vaccine in People at High-Risk of Developing Severe COVID-19 Symptoms
|
||
| Completed |
NCT04348214 -
Screening & Risk Assessment of Healthcare Workers & Infection Control in University & COVID-19 Quarantine Hospitals
|
||
| Not yet recruiting |
NCT04348877 -
Plasma Rich Antibodies From Recovered Patients From COVID19
|
N/A | |
| Not yet recruiting |
NCT04346043 -
To Access the Egyptian COVID-19 Whole Genome by NGS and Compare to the International Worldwide Database
|
||
| Not yet recruiting |
NCT04350931 -
Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19
|
Phase 3 |